Nifty
Sensex
:
:
11662.60
39131.04
74.25 (0.64%)
234.33 (0.60%)

Pharmaceuticals & Drugs

Rating :
65/99  (View)

BSE: 532523 | NSE: BIOCON

258.00
5.30 (2.10%)
16-Jul-2019 | 3:29PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  252.95
  •  258.80
  •  250.00
  •  252.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2313732
  •  5969.43
  •  359.00
  •  230.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 30,318.00
  • 33.49
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,683.80
  • 0.20%
  • 4.80

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.00%
  • 11.66%
  • FII
  • DII
  • Others
  • 1.21%
  • 3.71%
  • 22.75%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.82
  • 12.28
  • 12.32

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.45
  • 14.90
  • 7.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 12.70
  • 14.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.21
  • 24.45
  • 44.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.71
  • 4.46
  • 5.62

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.56
  • 20.73
  • 26.55

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
1,528.80
1,169.50
30.72%
1,540.80
1,057.90
45.65%
1,321.00
968.60
36.38%
1,123.80
933.70
20.36%
Expenses
1,125.80
936.50
20.21%
1,160.10
836.20
38.73%
981.40
786.30
24.81%
886.00
741.60
19.47%
EBITDA
403.00
233.00
72.96%
380.70
221.70
71.72%
339.60
182.30
86.29%
237.80
192.10
23.79%
EBIDTM
26.36%
19.92%
24.71%
20.96%
25.71%
18.82%
21.16%
20.57%
Other Income
28.20
67.50
-58.22%
25.60
33.90
-24.48%
54.40
50.80
7.09%
68.80
54.00
27.41%
Interest
15.90
16.90
-5.92%
18.60
14.70
26.53%
18.80
13.80
36.23%
17.60
16.10
9.32%
Depreciation
119.80
95.30
25.71%
116.70
97.40
19.82%
112.20
93.60
19.87%
99.10
98.80
0.30%
PBT
295.50
188.30
56.93%
276.80
143.50
92.89%
451.80
125.70
259.43%
189.90
131.20
44.74%
Tax
40.90
40.70
0.49%
46.10
36.10
27.70%
73.20
42.50
72.24%
52.10
37.60
38.56%
PAT
254.60
147.60
72.49%
230.70
107.40
114.80%
378.60
83.20
355.05%
137.80
93.60
47.22%
PATM
16.65%
12.62%
14.97%
10.15%
28.66%
8.59%
12.26%
10.02%
EPS
1.78
2.17
-17.97%
3.62
1.53
136.60%
5.91
1.15
413.91%
2.00
1.36
47.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
-
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
Net Sales Growth
-
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
 
Cost Of Goods Sold
-
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
Gross Profit
-
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
GP Margin
-
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
Total Expenditure
-
4,120.70
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
Power & Fuel Cost
-
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
% Of Sales
-
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
Employee Cost
-
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
% Of Sales
-
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
Manufacturing Exp.
-
451.30
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
% Of Sales
-
8.18%
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
General & Admin Exp.
-
53.00
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
% Of Sales
-
0.96%
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
Selling & Distn. Exp.
-
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
% Of Sales
-
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
Miscellaneous Exp.
-
37.20
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
56.49
% Of Sales
-
0.67%
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
EBITDA
-
1,393.70
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
EBITDA Margin
-
25.27%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
Other Income
-
144.40
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
Interest
-
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
Depreciation
-
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
PBT
-
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
Tax
-
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
Tax Rate
-
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
PAT
-
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
PAT before Minority Interest
-
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
Minority Interest
-
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
PAT Margin
-
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
PAT Growth
-
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
 
Unadjusted EPS
-
15.30
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
Share Capital
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
Non-Current Liabilities
2,123.20
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
Secured Loans
1,539.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
Unsecured Loans
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
Long Term Provisions
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
Current Liabilities
3,037.60
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
Trade Payables
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
Other Current Liabilities
1,373.80
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
Short Term Borrowings
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
Short Term Provisions
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
Total Liabilities
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
Net Block
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
Gross Block
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
Accumulated Depreciation
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
Non Current Assets
7,044.90
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
Capital Work in Progress
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
Non Current Investment
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
Long Term Loans & Adv.
401.50
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
Other Non Current Assets
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
Current Assets
4,822.80
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
Current Investments
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
Inventories
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
Sundry Debtors
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
Cash & Bank
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
Other Current Assets
612.90
373.30
395.80
73.60
171.60
157.60
136.90
114.30
56.70
136.10
Short Term Loans & Adv.
46.40
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
Net Current Assets
1,785.20
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
Total Assets
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,154.60
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
PBT
1,214.90
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
Adjustment
260.30
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
Changes in Working Capital
-29.10
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
Cash after chg. in Working capital
1,446.10
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-291.50
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-713.80
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
Net Fixed Assets
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
Net Investments
184.70
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
Others
-617.90
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
Cash from Financing Activity
-241.70
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
Net Cash Inflow / Outflow
199.10
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
Opening Cash & Equivalents
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
Closing Cash & Equivalent
659.30
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
50.17
85.19
79.49
67.22
53.86
48.42
43.18
36.31
32.49
28.25
ROA
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
ROE
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
ROCE
16.10%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
Fixed Asset Turnover
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
Receivable days
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
Inventory Days
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
Payable days
86.75
87.96
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
Cash Conversion Cycle
49.26
58.09
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
Total Debt/Equity
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
Interest Cover
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81

News Update


  • USFDA completes inspection at Biocon’s Insulins facilities in Malaysia
    8th Jul 2019, 09:25 AM

    The inspection across these 3 units concluded with 12 observations issued on the Form 483

    Read More
  • Biocon to sell BFI Business to Biocon Biologics
    18th Jun 2019, 08:58 AM

    The Board of Directors of the Company at its meeting held on June 17, 2019 has approved the same

    Read More
  • Biocon receives EU GMP Certification for Biologics facilities in Bengaluru
    14th Jun 2019, 14:17 PM

    These facilities, used for the manufacture of company’s portfolio of biosimilars, were inspected by the European agency in March 2019

    Read More
  • Health Canada approves Biocon & Mylan's Ogivri
    23rd May 2019, 14:34 PM

    Ogivri is the first trastuzumab biosimilar approved in Canada

    Read More
  • Biocon, Mylan to present final data from HERITAGE study in Chicago
    16th May 2019, 12:49 PM

    The HERITAGE study compared Ogivri to the reference product, Herceptin, in patients with HER2+ metastatic breast cancer

    Read More
  • Biocon retains economic interest in global commercialization of Hulio in-licensed by Mylan
    8th May 2019, 11:27 AM

    Biocon is committed to enable patient access to affordable biosimilars

    Read More
  • Biocon reports 64% rise in Q4 consolidated net profit
    26th Apr 2019, 11:33 AM

    Total consolidated income of the company rose 25.87% at Rs 1,557.00 crore for quarter ended March 31, 2019

    Read More
  • Biocon - Quarterly Results
    25th Apr 2019, 19:12 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.